Skip to main content

White paper: Antibody-Drug Conjugates

White paper

The Role of Diagnostics in Advancing Antibody-Drug Conjugates

Learn how Quest Diagnostics offers the expertise, infrastructure, and end-to-end support needed to accelerate ADC development—from assay design to clinical adoption.

 

This white paper is free and can be downloaded and read at your convenience.

Microscope analyzing cancer cells, symbolizing precise cancer diagnostics and treatment. Generative Ai

Antibody-drug conjugates: precision therapeutics powered by diagnostic innovation

Antibody-drug conjugates (ADCs) represent one of the most exciting advancements in precision oncology, combining the targeting power of monoclonal antibodies with potent cytotoxic therapies to destroy cancer cells while sparing healthy tissue. With over 180 ADCs in development and a surge of FDA approvals, these therapies are transforming cancer treatment and sparking unprecedented investments in the biopharma industry.

But ADC success doesn’t happen by chance. Diagnostic testing plays a critical role at every stage of development, from validating therapeutic targets to guiding patient selection and ensuring safe, effective treatment delivery. Robust, innovative diagnostics, including companion diagnostics (CDx), are the foundation for matching the right patients to the right therapies, driving clinical and commercial success.

In this white paper, we explore:

  • The science behind ADCs and their modular design
  • The essential role of diagnostic testing, including antigen validation and CDx development
  • Key capabilities pharmaceutical partners should look for in a diagnostic partner

Ready to take your ADC program to the next level?

Download the White Paper to discover how precision diagnostics power the future of antibody-drug conjugates.

Don't miss out on the future of cancer therapy advancements 

782

* indicates required